Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Roche, Morphosys Drug Cut Peptide Build-Up in Alzheimer’s Study

Don't Miss Out —
Follow us on:

Oct. 10 (Bloomberg) -- Roche Holding AG and Morphosys AG’s experimental Alzheimer’s treatment gantenerumab appeared to reduce the build-up in the brain of beta amyloid plaque thought to be linked to the disease, according to a study published today in Archives of Neurology.

Roche, based in Basel, Switzerland, sponsored the 16-person study, which wasn’t intended to prove whether gantenerumab helps patients. The drug is already being tested in a bigger mid-stage study to help determine its effectiveness for people with early symptoms of Alzheimer’s disease.

To contact the reporter on this story: Naomi Kresge in Berlin at nkresge@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.